Gen AI can create diverse content and data formats, revolutionizing the AI landscape and transforming businesses. The pharmaceutical industry can use gen AI to sift through vast clinical data volumes, enabling trial protocols’ drafting and improving clinical trial success rates. In this viewpoint, we present Everest Group’s findings from a survey of 50 pharmaceutical enterprises to evaluate their gen AI expectations, its adoption patterns, and insights into the technology’s role in clinical development. The report offers detailed insights into gen AI’s applications, potential impact, adoption challenges, and best practices to achieve a strategic advantage in the dynamic technology landscape. Pharmaceutical companies can use this report to gain valuable peer perspectives on gen AI, identify essential functionalities when choosing tools/platforms, and understand gen AI’s role in achieving business objectives. Scope Industry: pharmaceutical Geography: global Contents In this report, we: Assess pharmaceutical enterprises’ gen AI objectives Evaluate investment strategies and procurement initiatives to implement gen AI solutions Identify gen AI’s adoption challenges Recommend an enterprise framework to adopt and scale gen AI initiatives Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by leveraging digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the aftermath of the pandemic, a hybrid model is emerging that seamlessly integrates technology with traditional site workflows, ushering in a new era of clinical trials that harnesses the strengths of both approaches. In a financially constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They prioritize delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process. This compendium provides detailed and fact-based snapshots of 22 DCT providers. Each profile offers a comprehensive picture of the provider’s offerings, technology solutions, key clients, recent developments, and investments. Scope Industry: Life sciences Geography: global Contents This report features 22 DCT platform provider profiles and includes: Company overview: the company’s mission, client base, and revenue split across buyer segment and geographies Case studies demonstrating DCT capabilities Solutions/Products enabling DCT capabilities Recent product developments, partnerships, and investment areas Membership(s) Clinical Development Technology Outsourcing Excellence

Decentralized Clinical Trials (DCTs) are transforming the landscape of clinical research by harnessing digital technologies to facilitate remote patient participation. This patient-centric approach not only benefits participants but also ensures more inclusive and robust study results while reducing the workload for investigators. In the post-pandemic climate, a hybrid model is emerging that seamlessly integrates technology advances with traditional site workflows, creating a new era of clinical trials that harnesses the strengths of both. In a funding-constrained environment, DCT platform providers are looking to strike a balance between client satisfaction and cost reduction. They are focusing on delivering comprehensive solutions that include real-world evidence, integration with sensors and wearables, and tools dedicated to enhancing patient engagement and retention throughout the trial process. In this report, we assess the capabilities of 22 platform providers specific to the decentralized clinical trial landscape. These platform providers are mapped on the Everest Group PEAK Matrix® , a composite index of a range of distinct metrics related to a provider’s capability and market impact. Scope Industry: Life sciences clinical development technology Geography: global Contents In this report, we: Examine the provider landscape for DCTs Assess DCT platform providers on several capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management

In recent years, the emergence of digital tools and technologies has brought significant change in clinical research and trials. While traditional clinical trials have long been the gold standard for evaluating medical interventions, the proliferation of digital solutions has introduced complexities in managing multiple systems, data silos, and non-interoperable platforms. The patient and sponsor experiences suffer due to the presence of multiple disjointed systems and interfaces, leading to challenges in accessing and managing medical information. These challenges have sparked an urgent need to develop a unified approach that can streamline clinical trials and seamlessly integrate diverse technologies and data sources. The vision of a unified approach to transform clinical trials is fueled by the recognition of these challenges and the understanding that embracing digital technologies alone is not enough. To fully harness the potential of these tools, a cohesive and harmonized ecosystem is required, one in which data flows seamlessly, and technologies complement each other. This viewpoint offers a comprehensive view on a unified platform approach in clinical development, highlighting the key business challenges that enterprises face and the advantages of adopting such platforms. The report also outlines the architecture of these unified clinical development platforms and the benefits they offer to various stakeholders. Additionally, it provides a framework for life sciences companies to transition to this approach and offers recommendations for a successful implementation. Scope Industry: life sciences Geography: global Contents In this report, we present: An overview of a unified platform approach to clinical development including key business challenges that enterprises face and the benefits of adopting such platforms An overview of the architecture of a unified clinical development platform and stakeholder benefits that these platforms can unlock A framework for life sciences enterprises to transition to a unified platform approach and recommendations for success Membership(s) Clinical Development Technology Sourcing and Vendor Management

The pandemic accelerated the need to extract value from data due to the substantial increase in data generation from various clinical sources, characterized by high veracity, variety, and volume. As a result, the adoption of clinical Data and Analytics (D&A) platforms in clinical development has notably surged. This prompted a considerable interest in assessing their impact on clinical trials, patient care, treatment outcomes, and health system efficiency. The integration of complex clinical data sources including Electronic Health Records (EHR), Electronic Medical Records (EMR), laboratory data, Clinical Trial Management Systems (CTMS), connected devices, and Real-world Data (RWD), presents a significant challenge that the industry currently faces. Clinical D&A platforms provide significant benefits in the realm of clinical development. These platforms enhance data management by facilitating centralized and standardized data collection from various sources, resulting in improved data quality and integrity. Real-time monitoring capabilities enable stakeholders to track trial progress, identify potential issues, and make informed decisions. Advanced analytics tools help uncover patterns, trends, and correlations within the data, providing valuable insights for optimizing trial protocols and treatment strategies. In this compendium, we provide comprehensive and fact-based snapshots of 14 platform providers specific to clinical D&A. In addition, each provider is positioned on Everest Group’s PEAK Matrix® for comparison. The compendium will enable providers to benchmark their capabilities against their competitors, while buyers of clinical D&A platforms will be able to assess the providers based on their desired set of capabilities. Scope Industry: life sciences Geography: global Contents In this report, we evaluate clinical D&A platform providers on their: Market adoption and capabilities Case studies and recent developments Strengths and limitations Sourcing considerations Membership(s) Clinical Development Technology Sourcing and Vendor Management

The pandemic accelerated the need to extract value from data as it led to a substantial increase in data generation from various clinical sources, characterized by high veracity, variety, and volume. As a result, there has been a notable surge in the adoption of clinical data and analytics platforms in clinical development. This has sparked considerable interest in assessing their impact on clinical trials, patient care, treatment outcomes, and health system efficiency. Currently, the industry faces a significant challenge in integrating complex clinical data sources, including Electronic Health Records (EHR), Electronic Medical Records (EMR), laboratory data, Clinical Trial Management Systems (CTMS), connected devices, and Real-world Data (RWD). Clinical data and analytics platforms offer significant benefits in the realm of clinical development. These platforms enhance data management by facilitating centralized and standardized data collection from various sources, resulting in improved data quality and integrity. Real-time monitoring capabilities enable stakeholders to track trial progress, identify potential issues, and make informed decisions promptly. Advanced analytics tools help uncover patterns, trends, and correlations within the data, providing valuable insights for optimizing trial protocols and treatment strategies. In this report, we assess 14 clinical Data and Analytics (D&A) platform providers. The providers are positioned on Everest Group’s PEAK Matrix®, a composite index of a range of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope: Industry: life sciences Geography: global Contents: In this report, we: Examine the provider landscape for clinical D&A platforms Assess clinical D&A platform providers on several capabilities and market success-related dimensions Membership(s) Clinical Development Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs) provide pharmaceutical companies with various benefits, including cost savings, improved patient recruitment and retention, flexible operations, and better data quality. While the technology and data to support DCTs existed before the pandemic, only a few pilots were conducted. Today, the need for remote patient- and site-centric trials has led to increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate, indicating that DCTs are a lasting trend. Additionally, advances in technology, innovative business models, increased wearables support, regulatory bodies’ push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this report, we analyze the current state of the DCT market and deep dive into its adoption, market trends, DCT platform providers’ landscape, enterprise view of DCT platform providers, Environment, Social, and Governance (ESG) initiatives, and emerging technology opportunities in the industry. Scope Industry: life sciences Geography: global Contents In this report, we: Study DCT adoption trends and market dynamics Examine the DCT platform provider landscape Provide an enterprise view of DCT providers Analyze ESG initiatives and emerging technology opportunities in the industry Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, flexibility in operations, and improved data quality. Before the pandemic, although the technology and data to support DCTs existed, only a few pilots were conducted. Today, the pressing need for remote patient- and site-centric trials has increased investments in DCTs, and the momentum is expected to accelerate going forward, indicating that DCTs are here to stay. Additionally, technology advances, innovative business models, increased wearables support, US FDA’s push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this compendium, we provide comprehensive and fact-based snapshots of 24 DCT platform providers. In addition, each provider is positioned on Everest Group’s PEAK Matrix®; for comparison. The compendium will enable providers to benchmark their capabilities against their competitors, while buyers of DCT platforms will be able to assess the providers based on their desired set of capabilities. Scope: Industry: life sciences Geography: global Contents: In this report, we evaluate DCT platform providers on their: Market adoption and capabilities Case studies and recent developments Strengths and limitations Sourcing considerations Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, flexibility in operations, and improved data quality. Before the pandemic, although the technology and data to support DCTs existed, only a few pilots were conducted. Today, the pressing need for remote patient- and site-centric trials has increased investments in DCTs by pharma enterprises, and the momentum is expected to accelerate going forward, indicating that DCTs are here to stay. Additionally, technology advances, innovative business models, increased wearables support, US FDA’s push to adopt DCTs, and a holistic approach to clinical trials have strengthened the DCT landscape. In this report, we assess the capabilities of 24 DCT platform providers. The providers are positioned on Everest Group’s PEAK Matrix®, a composite index of a range of distinct metrics related to the providers’ capabilities and market impact. The study will enable buyers to choose the best-fit provider based on their sourcing considerations, while providers will be able to benchmark their performance against each other. Scope: Industry: life sciences Geography: global Contents: In this report, we: Examine the provider landscape for DCTs Assess DCT platform providers on several capabilities and market success-related dimensions Membership(s) Life Sciences Information Technology Sourcing and Vendor Management

Clinical development platforms typically evolve with technology advances and scientific breakthroughs. Notably, the COVID-19 pandemic accelerated the adoption of digital technologies, data science, analytics, and automation tools, enabling remote services and preserving the continuity of care. A unified clinical development platform with improved data architecture and analytics capabilities can accelerate the drug development process and enrich the experience for sponsors, patients, and physicians. In recent years, the industry has pivoted from questioning the existence of end-to-end platforms to creating a near-term vision for adopting such platforms. Everest Group’s Clinical Development Platforms Products PEAK Matrix® Assessment 2022 looks at the vendor landscape of clinical development platforms and presents in-depth analysis and insights on these platforms. We assess the capabilities of 22 clinical development platform vendors and map them on the Everest Group PEAK Matrix®, a composite index of distinct metrics related to a vendor’s capability and market impact. Scope Industry: life sciences Geography: global Contents This report features 22 clinical development product vendors’ profiles and includes: Assessment of the product vendors on several capability and market success-related dimensions Detailed profiles of each product vendor, featuring case studies and recent developments Strengths and limitations of each vendor Buying sourcing considerations Membership(s) Life Sciences Information Technology Sourcing and Vendor Management